stoxline Quote Chart Rank Option Currency Glossary
  
Sana Biotechnology, Inc. (SANA)
10  0.54 (5.71%)    03-27 16:00
Open: 9.55
High: 10
Volume: 1,267,803
  
Pre. Close: 9.46
Low: 9.21
Market Cap: 2,204(M)
Technical analysis
2024-03-27 4:55:36 PM
Short term     
Mid term     
Targets 6-month :  14.01 1-year :  16.37
Resists First :  12 Second :  14.01
Pivot price 9.26
Supports First :  9.41 Second :  7.81
MAs MA(5) :  9.36 MA(20) :  9.46
MA(100) :  6.04 MA(250) :  5.52
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  63.8 D(3) :  46.6
RSI RSI(14): 62.1
52-week High :  12 Low :  2.74
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SANA ] has closed Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.01 - 10.05 10.05 - 10.09
Low: 9.11 - 9.15 9.15 - 9.19
Close: 9.92 - 9.99 9.99 - 10.07
Company Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Headline News

Tue, 26 Mar 2024
Is Sana Biotechnology Inc (SANA) Stock a Bad Value Tuesday? - InvestorsObserver

Mon, 25 Mar 2024
Is Sana Biotechnology Inc (SANA) a Winner in the Biotechnology Industry? - InvestorsObserver

Sat, 23 Mar 2024
Citigroup Inc. Raises Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World

Wed, 13 Mar 2024
Institutional investors may overlook Sana Biotechnology, Inc.'s (NASDAQ:SANA) recent US$119m market cap drop as long-term gains remain positive - Simply Wall St

Mon, 11 Mar 2024
Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA) - Yahoo Finance

Mon, 04 Mar 2024
Students learn about biotechnology industry at BioBreakthrough Conference - Mustang News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 220 (M)
Shares Float 129 (M)
Held by Insiders 9.3 (%)
Held by Institutions 79.3 (%)
Shares Short 21,050 (K)
Shares Short P.Month 21,420 (K)
Stock Financials
EPS -1.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.45
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -29.5 %
Return on Equity (ttm) -72 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.38
Qtrly Earnings Growth 0 %
Operating Cash Flow -254 (M)
Levered Free Cash Flow -200 (M)
Stock Valuations
PE Ratio -6.85
PEG Ratio 0
Price to Book value 6.89
Price to Sales 0
Price to Cash Flow -8.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android